Ena Respiratory
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
31 Queen St, Melbourne, Victoria, 3000, ...Website
www.enarespiratory.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Ena Respiratory
Founded in 2020, Ena Respiratory aiming to transform the treatment and prevention of respiratory infections in at-risk populations. Ena Respiratory is developing novel, synthetic innate immunomodulators for the prevention of respiratory viral and bacterial infections. The company is based in Melbourne and Sydney, Australia. It has secured a Series A investment from the Brandon Capital managed Medical Research Commercialisation Fund (MRCF) and Uniseed.Explore more
Ena Respiratory Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ena Respiratory your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Ena Respiratory recently announced quarterly report
Funding: Get notified immidiatlly once Ena Respiratory has new funding data
Ena Respiratory, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Ena Respiratory had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Ena Respiratory is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Ena Respiratory has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Ena Respiratory launches new products
Congratulate Masked Content for being promoted to Masked Content at Ena Respiratory
Recommended Actions
Reach out to Masked Content who joined Ena Respiratory as Masked Content
Find more new buyers
Compare Similar Companies to Ena Respiratory
Compare insights from companies similar to Ena Respiratory, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
-
-
WT
Wayne TilleyHead Director, Initial Australian Node, The Dame Roma Mitchell Cancer Research Laboratories (South)
Company Profile Activity
Activity Insights
Ena Respiratory is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ena Respiratory is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ena Respiratory.
Ena Respiratory financials insights
Gather financial insights about Ena Respiratory, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$7.6M
2021
Other Financing Round
$24.6M
2025
Other Financing Round
$5M
Series B
$22.4M
Ena Respiratory Tech Stack
A closer look at the technologies used by Ena Respiratory
Most Recent Scoops
Person-Based
Person-Based
Funding
Funding
Person-Based
Person-Based
Ena Respiratory News & Media
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
MELBOURNE, Australia, May 11, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the successful completion of Part A of its Phase IIa community study of INNA-051, and progression to Part B.ENA Respiratory Appoints Melissa Faris to Board
MELBOURNE, Australia, April 23, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the appointment of Melissa Faris as an independent Non-Executive Director.ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces it has dosed the first participants in its Phase II community study of INNA-051, [with the first participant dosing now completed].ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
MELBOURNE, Australia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today that it has raised US$22.4m (AUD$34m) in its Series B financing.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ena Respiratory
Sign Up For FreeTo access detailed company insights
Founded in 2020, Ena Respiratory aiming to transform the treatment and prevention of respiratory infections in at-risk populations. Ena Respiratory is developing novel, synthetic innate immunomodulators for the prevention of respiratory viral and bacterial infections. The company is based in Melbourne and Sydney, Australia. It has secured a Series... Read More
